News

People with atypical hemolytic uremic syndrome (aHUS) who started treatment with Soliris (eculizumab) less than 15 days after symptom onset were much more likely to recover kidney function and stop dialysis within six months, an analysis of post-marketing surveillance data in Japan suggests. Among these patients, the shorter…

A 21-year-old man with atypical hemolytic uremic syndrome (aHUS) associated with Castleman disease improved after receiving treatment with iptacopan and Sylvant (siltuximab), according to a case report. Castleman disease presents symptoms that mimic aHUS due to the overgrowth of lymph nodes. Iptacopan is marketed as Fabhalta for…

The case of a 29-year-old woman who developed pregnancy-associated atypical hemolytic uremic syndrome (aHUS) along with uncommon lung complications after giving birth by cesarean section was reported in Mexico. Despite in-hospital complications, initial management that included corticosteroids yielded favorable results, although the woman still had significant kidney damage requiring hemodialysis,…

People with atypical hemolytic uremic syndrome (aHUS) who completed self-assessments for a study scored lower on measures of  physical and cognitive functioning than the general population. Patients reported higher levels of fatigue, anxiety, depression, and sleep disturbances, with “chronically impaired global health status,” the researchers wrote in what they…

A 26-year-old woman who developed pregnancy-associated atypical hemolytic uremic syndrome (p-aHUS) successfully recovered following treatment with Soliris (eculizumab), according to a case report from China. This case provides “a valuable reference for the timing, efficacy, and safety of complement blockade in p-aHUS [pregnancy-associated aHUS],” according to researchers. They added that the “successful…

After standard therapies failed, a 59-year-old man with lupus-related atypical hemolytic uremic syndrome (aHUS) improved when doctors gave him the oral medication iptacopan alongside one cycle of immunosuppressant rituximab, according to a case report from Italy. Iptacopan, marketed as Fabhalta, is an oral therapy approved for other diseases driven…

A never-before-reported mutation in the CD46 gene was found to contribute to the development of atypical hemolytic uremic syndrome (aHUS) in a young man in China, a study reports. According to researchers, “this finding broadens the spectrum of CD46 gene variants associated with aHUS, providing a critical basis for clinical diagnosis, genetic…

Two infections — influenza followed by COVID-19 — were trigger events for separate episodes of atypical hemolytic uremic syndrome (aHUS) in a young man in Japan, a case study reports. The researchers noted that the man’s “[two] episodes of recurrent aHUS following respiratory tract infections” resolved without the need…

Pericardial effusion — a potentially life-threatening disorder marked by the buildup of fluid around the heart — can affect people with atypical hemolytic uremic syndrome (aHUS), though it may not cause obvious symptoms, and aHUS patients should be screened for it, scientists said. The scientists, after reading a…

For this year’s aHUS Awareness Day — held annually on Sept. 24 — advocates worldwide will focus on managing the rare disease, asking people with atypical hemolytic uremic syndrome (aHUS) to share the single best decision they’ve made regarding their care. “Atypical hemolytic uremic syndrome impacts every aspect of…